Odyssey Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-160.03	-148.65	-129.32	-125.94	-124.67
Depreciation & Amortization	4.56	4.91	5.19	4.91	2.76
Stock-Based Compensation	15.89	14.32	8.69	6.26	5.52
Other Adjustments	15.33	4.67	1.28	1.15	17.09
Changes in Accounts Payable	0.76	2.06	-1.7	2.24	3.27
Changes in Accrued Expenses	1.19	-4.15	3.13	-1.08	6.88
Changes in Other Operating Activities	-9.83	-2.64	-4.74	-0.26	-10.69
Operating Cash Flow	-132.13	-129.47	-117.47	-112.73	-99.84
Operating Cash Flow Growth	-	-	-	-	-
Capital Expenditures	-0.61	-1.23	-0.76	-5.06	-13.03
Sale of Property, Plant & Equipment	0.5	0.36	-	0.02	-
Purchases of Investments	-455.46	-208.97	-52.61	-238.11	-
Proceeds from Sale of Investments	117.55	105.9	150.16	78.12	-
Investing Cash Flow	-338.02	-103.94	96.78	-165.02	-13.03
Long-Term Debt Issued	-	-	-	-4.76	4.88
Net Long-Term Debt Issued (Repaid)	-	-	-	-4.76	4.88
Issuance of Common Stock	4.18	3.19	0.51	0.26	0.08
Net Common Stock Issued (Repurchased)	4.18	3.19	0.51	0.26	0.08
Issuance of Preferred Stock	93.71	212.46	27.48	96.57	177.77
Net Preferred Stock Issued (Repurchased)	93.71	212.46	27.48	96.57	177.77
Other Financing Activities	-0.21	-	-1.01	-	-
Financing Cash Flow	389.37	215.65	26.98	92.08	182.72
Foreign Exchange Rate Adjustments	0.05	0.32	0.05	0.01	-0.02
Net Cash Flow	-80.73	-17.45	6.34	-185.67	69.83
Free Cash Flow	-132.74	-130.7	-118.24	-117.78	-112.87
Free Cash Flow Growth	-	-	-	-	-
FCF Margin	-134080.00%	-4391.80%	-2643.90%	-11358.10%	-
Free Cash Flow Per Share	-11.62	-43.02	-134.38	-181.76	-252.05
Levered Free Cash Flow	-163.96	-149.7	-129.28	-134.93	-130.6
Unlevered Free Cash Flow	-174.1	-157.18	-136.4	-133.46	-139.07

SEC Filings: 10-K · 10-Q